Free Trial
NASDAQ:OCS

Oculis Q4 2024 Earnings Report

Oculis logo
$16.35 -0.98 (-5.65%)
Closing price 04:00 PM Eastern
Extended Trading
$16.39 +0.04 (+0.21%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled. Check back for transcripts, audio, and key financial metrics as they become available.

Oculis Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Oculis to Participate in Upcoming September Investor Conferences
Oculis to Participate in Upcoming September Investor Conferences
Needham & Company LLC Initiates Coverage on Oculis (NASDAQ:OCS)
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat